Blood Science Update|In Vitro Erythropoiesis: The Emerging Potential of Induced Pluripotent Stem Cells (iPSCs)

Blood Science Update|In Vitro Erythropoiesis: The Emerging Potential of Induced Pluripotent Stem Cells (iPSCs)

2025.04.17
Despite over 100 million units of blood being donated annually, supply remains insufficient, particularly for patients with chronic conditions or in crisis settings. Alloimmunization and blood group incompatibilities further constrain transfusion efficacy. In response, researchers are exploring the use of induced pluripotent stem cells (iPSCs) to generate red blood cells (RBCs) in vitro as a reliable and potentially limitless source of transfusable cells. The journal Blood Science (2025) presents a comprehensive review of the current progress, challenges, and future directions of iPSC-derived erythropoiesis.
CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders

CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders

2025.04.17
At the 2025 China National Breast Cancer Conference, CSCO President and Director of Shandong Cancer Hospital, Academician Jinming Yu, delivered a keynote address titled “Precision Integration of Radiotherapy and Immunotherapy in Breast Cancer.” His presentation explored not only the evolving role of radiotherapy in breast cancer treatment but also offered key insights into strengthening China’s scientific innovation capacity in oncology. Following the session, Oncology Frontier invited Academician Yu to share his perspectives on the clinical application of radiotherapy in breast cancer, strategies for advancing China's global competitiveness in oncology, and his long-standing commitment to cultivating young academic talent.